Ray Therapeutics Secures PRIME Designation from the European Medicines Agency for RTx-015 Targeting Retinitis Pigmentosa Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company focused on developing innovative therapies for vision restoration, has announced that the European Medicines Agency (EMA) has granted…
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of its concurrent public…
Bepirovirsen advances to regulatory review by the European Medicines Agency as a promising first-in-class therapy for chronic hepatitis B GSK plc has announced a significant regulatory milestone as the European Medicines Agency (EMA) has formally accepted for review its marketing…
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…
Novo Nordisk broadens U.S. patient access to FDA-approved semaglutide treatments through Hims & Hers following a strategic shift in its U.S. GLP-1 business approach. Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that…
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon™ peptide platform to…
Funding Boosts Development of NanoGalaxy Platform and Lead Candidate BRZ-101 for Type 1 Diabetes Why is targeted gene delivery a critical challenge in the biotech industry? BreezeBio, a biotechnology company headquartered in South San Francisco, is addressing this issue with…
Grifols Secures European Medicines Agency Approval for Grifols Egypt’s Full Value Chain Grifols, S.A., a global leader in plasma-derived medicines and innovative healthcare solutions, has received certification from the European Medicines Agency (EMA) for the entire value chain of Grifols…
Blueprint Medicines presents long-term AYVAKIT® benefits in indolent and advanced systemic mastocytosis at ASH 2025. Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term AYVAKIT® (avapritinib) use across the spectrum of systemic mastocytosis (SM),…
Egypt Achieves Historic Milestone in Healthcare Sovereignty: Becomes Sixth Nation to Attain Plasma Self-Sufficiency with Grifols Partnership Plasma-derived medicines—a feat made possible through a groundbreaking five-year strategic alliance with Grifols, S.A. the global leader in plasma-derived therapies and healthcare innovation.…
Parabilis Medicines Announces Compelling Preliminary Clinical Results for FOG-001 in Adamantinomatous Craniopharyngioma at SNO 2025 Parabilis Medicines, a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with cancer, announced new preliminary clinical data highlighting the therapeutic promise of…
BeOne Medicines Demonstrates Scientific Leadership in B-Cell Cancers at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a rapidly expanding global oncology innovator, is set to showcase one of the most comprehensive and data-rich hematology portfolios at…